Written by Peter Liu
Spoon Feed
Atorvastatin provided a therapeutic and steroid-sparing effect in patients with pulmonary sarcoidosis.
Statin instead of steroid for patients with pulmonary sarcoidosis?
For patients with symptomatic pulmonary sarcoidosis, the mainstay of treatment remains systemic corticosteroids. Goals of therapy include maintenance of cardiopulmonary health as well as minimization of long-term steroid toxicity. This phase II RCT study performed at the NIH investigated whether atorvastatin 80mg daily provides a steroid-sparing effect in patients with pulmonary sarcoidosis. The trial randomized 55 patients with pulmonary sarcoidosis (Scadding stages II-IV) who had no other indications for statin use into placebo or atorvastatin groups, stratified by disease severity, with a protocol-driven prednisone taper over 12 months. The median steroid-sparing period (time at target prednisone dose) was 297.5 days for atorvastatin vs. 247 days for placebo (p=0.09). Several secondary outcomes also favored the atorvastatin arm, including a difference in diffusion capacity (DLCO) of 8.07% (p=0.05), improved Traditional Dyspnea Indices scores (TDI; p=0.032), and better high-resolution CT scores (p=0.016). Average prednisone usage was also significantly lower in the atorvastatin cohort (3.8mg daily vs. 7.4mg daily p=0.01). Notably, the study suffered from under-enrollment for reasons not disclosed in the publication (study design was intended for 96 enrollees). These findings generally support the usage of statins for patients with radiographic stage II-IV pulmonary sarcoidosis requiring steroid therapy, and suggest benefits related to both improved pulmonary measures as well as reduced steroid usage.
How does this change my practice?
While the findings from this study are not definitive, they will prompt me to consider statin initiation in my patients who have symptomatic pulmonary sarcoidosis as a possible steroid-sparing and disease-modifying medication.
Source
Atorvastatin in Severity-stratified Pulmonary Sarcoidosis: A Phase II Randomized Controlled Trial. Am J Respir Crit Care Med. 2024 Dec 19. doi: 10.1164/rccm.202403-0526RL. Epub ahead of print. PMID: 39701029
Given the very limited quality of evidence – even if RCT, has many limitations to begin with a non-statistical significance, which is critical in a very low sample of a non-phase III trial with concerning signs regarding selection bias (under-enrollment and the sample itself) – added to the limited biological plausibility, I would strongly discourage start treating pulmonary sarcoidosis with statins until better evidence with better quality.